February 26, 2018 08:39 AM EST
Pharma

Sov­er­eign non­sense: Patent board joins the line­up of crit­ics diss­ing Al­ler­gan's 'il­lu­so­ry' IP deal with the Mo­hawks

John Carroll

Editor & Founder

Al­ler­gan’s $AGN at­tempt to make an end run around an in­ter partes re­view of its patents for its block­buster Resta­sis fran­chise has been dissed by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times